Equities Analysts Offer Predictions for TNGX Q1 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research note issued on Monday, April 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous forecast of ($0.34). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.52) EPS and FY2026 earnings at ($1.54) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The business had revenue of $4.12 million during the quarter, compared to analyst estimates of $7.84 million.

Tango Therapeutics Trading Down 6.9 %

TNGX stock opened at $1.28 on Wednesday. The company’s 50-day moving average price is $1.84 and its 200 day moving average price is $3.37. Tango Therapeutics has a 52 week low of $1.11 and a 52 week high of $12.02. The company has a market cap of $138.38 million, a P/E ratio of -1.08 and a beta of 1.03.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TNGX. State Street Corp increased its holdings in Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after purchasing an additional 142,710 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Tango Therapeutics in the 4th quarter valued at approximately $2,031,000. Swiss National Bank increased its position in Tango Therapeutics by 13.1% during the fourth quarter. Swiss National Bank now owns 94,900 shares of the company’s stock worth $293,000 after buying an additional 11,000 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Tango Therapeutics by 12.4% in the fourth quarter. American Century Companies Inc. now owns 110,448 shares of the company’s stock valued at $341,000 after acquiring an additional 12,162 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the sale, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 24,268 shares of company stock worth $72,561. Company insiders own 6.30% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.